Briefing on some biotech stocks

Briefing on some biotech stocks

June 22, 2017 Off By Dino Mustafić

In a daily briefing, Daily Stock Tracker (DST) gave some insight on certain biotech stocks, noting that companies in this space are almost always unprofitable, and many have no real revenue at all.

The researcher said that California headquartered CytRx Corp.’s shares gained 4.28%, closing Wednesday’s trading session at $0.67. The stock recorded a trading volume of 4.48 million shares. The Company’s shares have surged 21.72% in the last month, 68.19% over the previous three months, and 78.72% since the start of this year. The stock is trading 17.44% above its 50-day moving average and 34.33% above its 200-day moving average. Additionally, shares of CytRx, which operates as a biopharmaceutical research and development company specializing in oncology, have a Relative Strength Index (RSI) of 52.18.

On June 13th, 2017, CytRx announced that Shanta Chawla, M.D., who has served as the Company’s Vice President of Clinical Development since 2014, is being promoted to Senior Vice President of Drug Development, and will assume the leadership of the Company’s on-going clinical drug development and regulatory functions. Chawla, who is a Board certified physician, has played a key role in the late-stage development and NDA submissions of several oncology drugs, and has been involved in the day-to-day clinical development of aldoxorubicin for more than three years.

On Wednesday, shares in Boston, Massachusetts headquartered Keryx Biopharmaceuticals Inc. recorded a trading volume of 1.45 million shares, which was above their three months average volume of 1.35 million shares. The stock edged 3.94% higher, ending the day at $6.33. The Company’s shares have advanced 0.16% in the past month, 16.15% in the previous three months, and 8.02% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.80% and 13.14%, respectively. Furthermore, shares of Keryx Biopharma, which focuses on providing medicines for patients with renal disease in the US, have an RSI of 51.69.

New York headquartered TG Therapeutics Inc.’s stock finished the day 3.15% higher at $11.45. A total volume of 1.74 million shares was traded, which was above their three months average volume of 1.70 million shares. Shares of the Company have advanced 3.15% in the previous three months and 146.24% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.94% and 45.35%, respectively. Additionally, shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the US, have an RSI of 49.93.

On June 16th, 2017, TG Therapeutics recapped clinical data from its Phase-3 GENUINE trial of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody in combination with ibrutinib, the BTK inhibitor. The GENUINE Phase-3 trial showed that adding TG-1101 to ibrutinib could improve overall response rate, CR rate, and MRD negativity in patients with high-risk Chronic Lymphocytic Leukemia.

 

Shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. ended yesterday’s session 1.90% higher at $5.89. The stock recorded a trading volume of 1.10 million shares. The Company’s shares have advanced 1.38% over the previous three months and 10.09% since the start of this year. The stock is trading 4.60% below its 200-day moving average. Moreover, shares of ZIOPHARM Oncology, which focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology, have an RSI of 46.38.

On June 01st, 2017, research firm H.C. Wainwright initiated a ‘Buy’ rating on the Company’s stock, with a target price of $9.50 per share.

On June 05th, 2017, ZIOPHARM Oncology announced updated results from its Phase-1 multicenter study of Ad-RTS-hIL-12 + veledimex, including the 20 mg expansion cohort in patients with recurrent or progressive glioblastoma. Median overall survival of all patients receiving intratumoral Ad-RTS-hIL-12 with 20 mg of orally administered veledimex was maintained at 12.5 months, with a mean follow-up time of 9.2 months.